HomeCompareDVAX vs EQR

DVAX vs EQR: Dividend Comparison 2026

DVAX yields 12.90% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DVAX wins by $6.3K in total portfolio value
10 years
DVAX
DVAX
● Live price
12.90%
Share price
$15.50
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$46.8K
Annual income
$2,879.44
Full DVAX calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — DVAX vs EQR

📍 DVAX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDVAXEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DVAX + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DVAX pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DVAX
Annual income on $10K today (after 15% tax)
$1,096.77/yr
After 10yr DRIP, annual income (after tax)
$2,447.52/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, EQR beats the other by $799.14/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DVAX + EQR for your $10,000?

DVAX: 50%EQR: 50%
100% EQR50/50100% DVAX
Portfolio after 10yr
$43.6K
Annual income
$3,349.52/yr
Blended yield
7.68%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

DVAX
Analyst Ratings
9
Buy
1
Hold
1
Sell
Consensus: Buy
Price Target
$27.00
+74.2% upside vs current
Range: $20.00 — $32.00
Altman Z
2.4
Piotroski
6/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DVAX buys
0
EQR buys
0
No recent congressional trades found for DVAX or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDVAXEQR
Forward yield12.90%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$46.8K$40.5K
Annual income after 10y$2,879.44$3,819.61
Total dividends collected$20.6K$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold
Analyst price target$27.00$70.35

Year-by-year: DVAX vs EQR ($10,000, DRIP)

YearDVAX PortfolioDVAX Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$11,990$1,290.32$11,248$547.57+$742.00DVAX
2$14,276$1,445.92$12,701$666.53+$1.6KDVAX
3$16,884$1,608.88$14,405$814.59+$2.5KDVAX
4$19,844$1,778.34$16,413$999.84+$3.4KDVAX
5$23,186$1,953.40$18,795$1,232.92+$4.4KDVAX
6$26,943$2,133.11$21,639$1,527.95+$5.3KDVAX
7$31,145$2,316.51$25,057$1,903.80+$6.1KDVAX
8$35,828$2,502.66$29,197$2,385.87+$6.6KDVAX
9$41,026$2,690.60$34,250$3,008.70+$6.8KDVAX
10$46,778$2,879.44$40,467$3,819.61+$6.3KDVAX

DVAX vs EQR: Complete Analysis 2026

DVAXStock

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.

Full DVAX Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this DVAX vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DVAX vs SCHDDVAX vs JEPIDVAX vs ODVAX vs KODVAX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.